Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID
18 hours ago
Outpatient use of nirmatrelvir/ritonavir lowers the risk of severe COVID-19-related outcomes, regardless of age or vaccination status, in a large, nationally representative cohort study in Taiwan, highlighting the importance of early antiviral treatment in ageing and unvaccinated populations.
Resources
Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID
Outpatient use of nirmatrelvir/ritonavir cuts risk of severe COVID